FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D C	20540
wasiiiigton,	D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMP Noveles	0005 0007							
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Carosella Deborah D</u>					2. Issuer Name and Ticker or Trading Symbol Arcadia Biosciences, Inc. [RKDA]						(Ch	eck all applic	nship of Reporting F applicable) Director		Person(s) to Issu 10% Owr	
	CADIA BIO	OSCIENCES, IN			Date o		Trans	action (Mont	n/Day/Year)		Officer below)	(give title		Other (specif below)		
202 COUSTEAU PLACE, SUITE 105				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Individual or Joint/Group Filing (Check Applicable Line)					
(Street) DAVIS	C	A										X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)													
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date				action 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Inst				5. Amour Securitie Beneficia Owned F Reported	es Feially (I Following (I	6. Ownersl Form: Dire (D) or Indir (I) (Instr. 4)	ct c	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			insu. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	e, Transaction of Ex Code (Instr. Derivative (N		6. Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year) T. Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transaction (Instr. 4)	y Own Forn Director In (I) (Ir	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$1.34	06/01/2022		Α		23,620		(1)	06/01/2032	Common Stock	23,620	\$0.00	56,408		D	

Explanation of Responses:

1. The Option will become 100% vested and exercisable on the earlier to occur of (i) June 1, 2023 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued

Remarks:

Deborah D. Carosella, by Attorney-in-Fact, Cesare Suardi

06/03/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).